Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A phospho specific peptide corresponding to residues surrounding Tyrosine 857 of human PDGF-Receptor ? was used as an immunogen. This antibody detects PDGF-Receptor ? phosphorylated at Tyrosine 857
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Human platelet-derived growth factor (PDGF) receptor, is a receptor tyrosine kinase whose activity induces various signalling cascades leading to cell growth and proliferation. Phosphorylation of Tyrosine 857 (pY857) in the catalytic loop of the PDGF Receptor beta has been shown to increase kinase activity. Two major isoforms exist, PDGF receptor-? and PDGF receptor-?. PDGF receptor-? can only bind two specific PDGF isoforms, PDGF-? and PDGF-? (1,2). Upon ligand binding, the receptor undergoes autophosphorylation, allowing binding and activation of cytoplasmic SH2 domain-containing signal transduction molecules such as PI kinase (3), Grb2, and Src, among others.
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on NIH3T3 cell lysates using anti-Phospho-PDGF-Receptor β (pY857), 1:1000 dilution. Cells were either (A) untreated (B) treated with PDGF.
Researchers who bought this antibody have also purchased:
